Literature DB >> 2846948

[Modification of atrial natriuretic peptide (ANP) and cyclic GMP by hemofiltration and hemodialysis].

T Eisenhauer1, J Talartschik, E Quentin, W Kreutzfeldt, F Scheler.   

Abstract

ANP and c-GMP concentrations in 7 patients with chronic renal failure (CRF) undergoing regular hemofiltration (HF) were determined. After switching to hemodialysis (HD) under identical ultrafiltration and treatment time no significant difference of the ANP and c-GMP profiles was detected, suggesting that the type of treatment does not affect ANP and c-GMP plasma levels. In both procedures a continuous decrease of ANP and c-GMP was observed. Head down tilting to compensate hypotension during HD was immediately followed by an increase in ANP and c-GMP during ultrafiltration. An acute onset of tachyarrhythmia absoluta during HD was also accompanied by a rise in ANP plasma concentrations. This demonstrates that ANP secretion is not altered in patients with CRF. Since ANP plasma levels closely correlate with intravascular volume, periodic determination of this hormone in HD/HF patients may provide diagnostic information to detect volume overload.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2846948     DOI: 10.1007/bf01728958

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  14 in total

1.  Atrial natriuretic factor--a new hormone affecting kidney function.

Authors:  H Sonnenberg
Journal:  Klin Wochenschr       Date:  1985-09-16

Review 2.  Atrial natriuretic hormone, the renin-aldosterone axis, and blood pressure-electrolyte homeostasis.

Authors:  J H Laragh
Journal:  N Engl J Med       Date:  1985-11-21       Impact factor: 91.245

Review 3.  The atrial natriuretic factor.

Authors:  J Genest
Journal:  Br Heart J       Date:  1986-10

4.  Plasma levels and dialysance of atrial natriuretic peptide in terminal renal failure.

Authors:  H Saxenhofer; M P Gnädinger; P Weidmann; S Shaw; D Schohn; C Hess; D E Uehlinger; H Jahn
Journal:  Kidney Int       Date:  1987-10       Impact factor: 10.612

5.  Atrial natriuretic peptide in plasma of volume-overloaded children with chronic renal failure.

Authors:  W Rascher; T Tulassay; R E Lang
Journal:  Lancet       Date:  1985-08-10       Impact factor: 79.321

6.  Hormonal regulation of water metabolism in children with nephrotic syndrome.

Authors:  W Rascher; T Tulassay
Journal:  Kidney Int Suppl       Date:  1987-08       Impact factor: 10.545

7.  [Is the plasma ANP level an index of volume expansion in dialysis patients?].

Authors:  J Talartschik; T Eisenhauer; E Voth; G Sold; F Scheler
Journal:  Z Kardiol       Date:  1988

8.  [Clinical relevance of the determination of plasma atrial natriuretic peptide in children with chronic renal failure].

Authors:  W Rascher; M Bald; F Kröner; T Tulassay; D E Müller-Wiefel
Journal:  Z Kardiol       Date:  1988

9.  Atrial natriuretic peptide in humans. Production and clearance by various tissues.

Authors:  I G Crozier; M G Nicholls; H Ikram; E A Espiner; T G Yandle; S Jans
Journal:  Hypertension       Date:  1986-06       Impact factor: 10.190

10.  Detection of fluid overload by plasma concentration of human atrial natriuretic peptide (h-ANP) in patients with renal failure.

Authors:  T Eisenhauer; J Talartschik; F Scheler
Journal:  Klin Wochenschr       Date:  1986
View more
  3 in total

1.  [Regulation of thirst in end-stage kidney insufficiency].

Authors:  E Heidbreder; U Bahner; M Hess; H Geiger; R Götz; R Kirsten; W Rascher; A Heidland
Journal:  Klin Wochenschr       Date:  1990-11-16

2.  Atrial natriuretic peptide and cyclic 3'5'-guanosine monophosphate as indicators of fluid volume overload in children with chronic renal failure.

Authors:  B Lettgen; M Bald; H Valleé; K E Bonzel; W Rascher
Journal:  Pediatr Nephrol       Date:  1992-01       Impact factor: 3.714

3.  The role of natriuretic peptides in volume assessment and mortality prediction in Haemodialysis patients.

Authors:  Murugan Sivalingam; Enric Vilar; Suresh Mathavakkannan; Ken Farrington
Journal:  BMC Nephrol       Date:  2015-12-29       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.